Daniel F. Sahm, PhD

VP Global Microbiology Services & Chief Scientific Officer
IHMA, Inc.

Disclosure: IHMA (Individual(s) Involved: Self): Employee; Pfizer, Inc. (Individual(s) Involved: Self): Consultant; Shionogi & Co., Ltd. (Individual(s) Involved: Self): Independent Contractor

Presentation(s):

• 164 - in Vitro Antibacterial Activity of Cefiderocol Against Non-fermenter Clinical Strains Collected in North America and Europe from Multinational Surveillance Studies SIDERO-WT-2014–2018

  Oral Abstract